Pulmonx Corp (LUNG) shareholders
Close on Nov 16, 2026Market cap $120.26MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Primecap Management Co/Ca/ | 4,408,431 | 10.26% | 13G (passive) amendment | Sep 30, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (6.80%) | 2,920,241 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Soleus Capital Management, L.P. Joint filing with Soleus Capital Master Fund, L.P. (6.50%), Soleus Capital, LLC (6.50%) and 3 more | 2,665,100 | 6.50% | 13G (passive) | Mar 6, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.40%) | 2,179,993 | 5.40% | 13G (passive) amendment | Aug 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LUNG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Primecap Management Co/Ca/ | 4,612,331 | 10.74% | $6.00M | −112,660 | 0.00% |
| Morgan Stanley | 2,922,921 | 6.81% | $3.80M | −1,070,641 | 0.00% |
| Soleus Capital Management, L.P. | 2,788,323 | 6.49% | $3.62M | – | 0.12% |
| Vanguard Capital Management LLC | 1,630,219 | 3.80% | $2.12M | −4,045 | 0.00% |
| ExodusPoint Capital Management, LP | 1,223,555 | 2.85% | $1.59M | −720,279 | 0.01% |
| Almitas Capital LLC | 1,064,202 | 2.48% | $1.38M | New | 0.33% |
| BlackRock, Inc. | 882,490 | 2.05% | $1.15M | −1,779,117 | 0.00% |
| Stonepine Capital Management, LLC | 815,436 | 1.90% | $1.06M | +47,148 | 0.60% |
| Jane Street Group, LLC | 758,231 | 1.77% | $985.70K | +624,961 | 0.00% |
| Braidwell LP | 752,541 | 1.75% | $978.30K | – | 0.04% |
| Aqr Capital Management LLC | 744,963 | 1.73% | $968.45K | +387,385 | 0.00% |
| Parkman Healthcare Partners LLC | 646,564 | 1.51% | $840.53K | −109,072 | 0.09% |
| Geode Capital Management, LLC | 452,684 | 1.05% | $588.71K | −491,808 | 0.00% |
| Renaissance Technologies LLC | 425,110 | 0.99% | $552.64K | +104,810 | 0.00% |
| ADAR1 Capital Management, LLC | 404,497 | 0.94% | $525.85K | +30,000 | 0.02% |
| Deutsche Bank AG\ | 402,316 | 0.94% | $523.01K | −761,362 | 0.00% |
| D. E. Shaw & Co., Inc. | 327,528 | 0.76% | $425.79K | −7,546 | 0.00% |
| Jefferies Financial Group Inc. | 285,110 | 0.66% | $370.64K | – | 0.00% |
| Cfm Wealth Partners LLC | 264,039 | 0.61% | $343.25K | – | 0.04% |
| Vanguard Fiduciary Trust Co | 250,511 | 0.58% | $325.66K | −30,737 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 108 | 26M | 61.0% | 20 / 36 | 35 / 25 | 4M | 10M |
| Q1 2026 | 114 | 32M | 74.0% | 22 / 38 | 37 / 17 | 5M | 3M |
| Q4 2025 | 112 | 32M | 75.5% | 24 / 30 | 38 / 18 | 7M | 6M |
| Q3 2025 | 107 | 32M | 75.3% | 20 / 35 | 29 / 26 | 5M | 9M |
| Q2 2025 | 113 | 36M | 84.4% | 23 / 34 | 35 / 25 | 4M | 4M |
| Q1 2025 | 115 | 36M | 84.6% | 15 / 42 | 31 / 17 | 4M | 4M |
| Q4 2024 | 118 | 36M | 83.9% | 23 / 36 | 34 / 15 | 3M | 4M |
| Q3 2024 | 113 | 37M | 85.3% | 27 / 37 | 30 / 22 | 7M | 3M |
| Q2 2024 | 112 | 36M | 83.4% | 21 / 40 | 32 / 26 | 5M | 9M |
| Q1 2024 | 118 | 40M | 93.7% | 18 / 35 | 42 / 22 | 8M | 4M |
| Q4 2023 | 123 | 36M | 84.3% | 21 / 42 | 37 / 13 | 8M | 4M |
| Q3 2023 | 117 | 33M | 77.5% | 11 / 39 | 44 / 9 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
95 funds held LUNG in Q1 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LUNG | Value | % of fund | As of |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Aggressive Growth Fund | 3,502,001 | 8.15% | $5.71M | 0.08% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,152,272 | 2.68% | $1.50M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 436,553 | 1.02% | $567.52K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 233,072 | 0.54% | $384.57K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 189,388 | 0.44% | $312.49K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 137,144 | 0.32% | $178.29K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 73,767 | 0.17% | $121.72K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 68,528 | 0.16% | $89.09K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 62,009 | 0.14% | $102.31K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 61,000 | 0.14% | $79.30K | 0.05% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 36,293 | 0.08% | $59.88K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,714 | 0.06% | $40.78K | 0.00% | May 31, 2026 |
| Large-Cap Growth Portfolio | 23,292 | 0.05% | $30.28K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 22,314 | 0.05% | $29.01K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 19,080 | 0.04% | $24.80K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Glendon E. French III | President and CEO, Director | 2,056,134 | 4.79% | Sep 3, 2026 |
| Steven S. Williamson | PRESIDENT AND CEO, Director | 363,497 | 0.85% | Sep 3, 2025 |
| David Aaron Lehman | General Counsel | 370,130 | 0.86% | Sep 3, 2026 |
| Srikanth Radhakrishnan | Chief Science & Techn. Officer | 326,475 | 0.76% | Sep 3, 2026 |
| Geoffrey Beran Rose | Chief Commercial Officer | 453,108 | 1.06% | Sep 3, 2026 |
| Derrick Sung | COO and CFO | 1,335,319 | 3.11% | Dec 3, 2025 |
| Mehul Joshi | Chief Financial Officer & PAO | 208,489 | 0.49% | Sep 3, 2025 |
| Thomas William Burns | Director | 113,399 | 0.26% | Jun 9, 2026 |
| Richard Ferrari | Director | 1,359,345 | 3.17% | Jun 9, 2026 |
| Georgia Melenikiotou | Director | 139,714 | 0.33% | Jun 9, 2026 |
| Dana G. Mead Jr. | Director | 143,790 | 0.33% | Jun 9, 2026 |
| Daniel P. Florin | Director | 149,699 | 0.35% | Jun 9, 2026 |
| Tiffany Sullivan | Director | 115,199 | 0.27% | Jun 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −2,121 | $2.26 | $4.79K | 326,475 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −3,618 | $2.26 | $8.18K | 322,857 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −5,863 | $2.26 | $13.25K | 316,994 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −2,643 | $2.26 | $5.97K | 328,596 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −2,224 | $2.26 | $5.03K | 370,130 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −3,476 | $2.26 | $7.86K | 366,654 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −4,827 | $2.26 | $10.91K | 361,827 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −3,807 | $2.26 | $8.60K | 372,354 |
| Glendon E. French III President and CEO, Director | Sep 1, 2026 | Sale | −37,784 | $2.26 | $85.39K | 1,137,936 |
| Glendon E. French III President and CEO, Director | Sep 1, 2026 | Sale | −4,098 | $2.26 | $9.26K | 1,175,720 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −2,390 | $2.26 | $5.40K | 453,108 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −1,746 | $2.26 | $3.95K | 449,832 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −1,530 | $2.26 | $3.46K | 451,578 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −2,213 | $2.26 | $5.00K | 455,498 |
| Thomas William Burns Director | Jun 5, 2026 | Award | +40,000 | – | – | 113,399 |
| Georgia Melenikiotou Director | Jun 5, 2026 | Award | +40,000 | – | – | 139,714 |
| Richard Ferrari Director | Jun 5, 2026 | Award | +40,000 | – | – | 127,024 |
| Tiffany Sullivan Director | Jun 5, 2026 | Award | +40,000 | – | – | 115,199 |
| Daniel P. Florin Director | Jun 5, 2026 | Award | +40,000 | – | – | 133,910 |
| Dana G. Mead Jr. Director | Jun 5, 2026 | Award | +40,000 | – | – | 139,714 |
| Glendon E. French III President and CEO, Director | Jun 2, 2026 | Sale | −13,511 | $1.57 | $21.21K | 1,178,162 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −2,434 | $1.54 | $3.75K | 459,965 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −2,254 | $1.54 | $3.47K | 457,711 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −1,778 | $1.54 | $2.74K | 463,956 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −1,557 | $1.54 | $2.40K | 462,399 |
| Glendon E. French III President and CEO, Director | Jun 1, 2026 | Sale | −38,467 | $1.54 | $59.24K | 1,191,673 |
| Glendon E. French III President and CEO, Director | Jun 1, 2026 | Sale | −4,171 | $1.54 | $6.42K | 1,230,140 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −2,153 | $1.54 | $3.32K | 340,892 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −2,691 | $1.54 | $4.14K | 343,045 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −5,969 | $1.54 | $9.19K | 331,239 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −3,684 | $1.54 | $5.67K | 337,208 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −2,264 | $1.54 | $3.49K | 384,615 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −3,876 | $1.54 | $5.97K | 386,879 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −4,915 | $1.54 | $7.57K | 376,161 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −3,539 | $1.54 | $5.45K | 381,076 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −2,590 | $1.43 | $3.70K | 244,806 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −4,051 | $1.43 | $5.79K | 240,755 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Award | +150,000 | – | – | 390,755 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −4,433 | $1.43 | $6.34K | 247,396 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −1,163 | $1.43 | $1.66K | 251,829 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −3,068 | $1.43 | $4.39K | 177,395 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −756 | $1.43 | $1.08K | 180,463 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Award | +175,000 | – | – | 345,736 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −2,461 | $1.43 | $3.52K | 174,934 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −4,198 | $1.43 | $6.00K | 170,736 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −1,861 | $1.43 | $2.66K | 368,645 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −835 | $1.43 | $1.19K | 372,631 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −2,125 | $1.43 | $3.04K | 370,506 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Award | +100,000 | – | – | 465,734 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −2,911 | $1.43 | $4.16K | 365,734 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −6,737 | $1.43 | $9.63K | 1,467,879 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −2,708 | $1.43 | $3.87K | 1,474,616 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −58,368 | $1.43 | $83.47K | 1,409,511 |
| Daniel P. Florin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −23,321 | $1.99 | $46.41K | 93,910 |
| Derrick Sung COO and CFO | Dec 1, 2025 | Award | +1,200,000 | – | – | 1,335,319 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Sale | −6,281 | $1.57 | $9.86K | 277,324 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Award | +1,200,000 | – | – | 1,477,324 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Sale | −2,524 | $1.57 | $3.96K | 283,605 |
| David Aaron Lehman GENERAL COUNSEL | Dec 1, 2025 | Sale | −3,401 | $1.57 | $5.34K | 252,992 |
| David Aaron Lehman GENERAL COUNSEL | Dec 1, 2025 | Sale | −976 | $1.57 | $1.53K | 262,294 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pulmonx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,297 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steven S. Williamson Officer, Director | Jan 22, 2026 | 48,892 | $95.34K | Jan 22, 2026 | Restricted Stock |
| Steven S. Williamson Officer, Director | Jan 15, 2026 | 15,892 | $31.04K | Jan 15, 2026 | Restricted Stock |
| Steven S. Williamson Officer, Director | Jan 14, 2026 | 31,082 | $62.07K | Jan 14, 2026 | Restricted Stock |
| Daniel P. Florin Director | Dec 8, 2025 | 23,321 | $46.39K | Dec 8, 2025 | Restricted Stock |
| Richard Ferrari Director | Jun 13, 2025 | 5,438 | $16.37K | Jun 13, 2025 | Open Market Purchase |
| Rich Ferrari Director | Jun 12, 2025 | 8,000 | $25.31K | Jun 12, 2025 | Restricted Stock |
| Glendon E. French III Director | Mar 20, 2025 | 60,000 | $466.20K | Mar 20, 2025 | Previously Exercised Options |
| David Aaron Lehman Officer | Mar 3, 2025 | 13,622 | $108.57K | Mar 3, 2025 | Restricted Stock |
| Glendon E. French III Officer | Feb 20, 2025 | 55,453 | $368.21K | Feb 20, 2025 | Previously Exercised Options |
| Glendon E. French III Director | Jan 17, 2025 | 2,221 | $14.21K | Jan 17, 2025 | Previously Exercised Options |
| Glendon E. French III Director | Jan 16, 2025 | 2,326 | $15.63K | Jan 16, 2025 | Previously Exercised Options |
| Glendon E. French III Officer | Nov 22, 2024 | 20,000 | $128.40K | Nov 22, 2024 | Previously Exercised Options |
| Glendon E. French III Officer | Oct 17, 2024 | 20,000 | $136.00K | Oct 17, 2024 | Previously Exercised Options |
| Glendon E. French III Director | Sep 12, 2024 | 20,000 | $155.00K | Sep 12, 2024 | Previously Exercised Options |
| Geoffrey Beran Rose Officer | Jun 24, 2024 | 1,184 | $7.29K | Jun 24, 2024 | Exercised Shares |
See a number that looks wrong?